گەشەپێدانی دەرمان دژی کۆڤید-١٩

گەشەپێدانی دەرمان دژی کۆڤید-١٩ پڕۆسەیەکە کە کاردەکرێ بۆ گەشەپێدانی دەرمان دژی ڤایرۆسی کۆڕۆنا، بە شێوەیەکی نێودەوڵەتی لە نۆڤێمبەری ٢٠٢٠ـەوە سەدان کۆمپانیای دەرمان و زانکۆ و پەیمانگا و نەخۆشخانەکان و ڕێکخراوە تەندروستیەکان کاریان کردووە و زیاتر لە ٥٠٠ چارەسەریان بۆ ڤایرۆسی کۆرۆنا دۆزیوەتەوە^[١]^[٢]^[٣]^[٤]

ڕێکخراوەی تەندروستیی جیھانی^[٥] و برێکاریەتی دەرمانی ئەوروپی ^[٦] و بەرێوەبەرایەتی خواردن و دەرمان^[٧] حکومەتی چین و کارگەکانی دەرمان^[٨]^[٩] پێکەوە بە شێوەی ئەکادیمی کاریان کرد بۆ خێرا گەشەپێدانی ڤاکسینەکان، دەرمانە دژە ڤایرۆسەکان، و چارەسەری دژی پێش توشبوون ^[١٠]^[١١]^[١٢]^[١٣]

ڕێکخراوی تەندروستی جیھانی لە ڕێپۆرتێکدا ٥٣٦ لێکۆلینەوەی پزیشکی لەسەر چارەسەر بۆ تووشبوون بە کۆڕۆنا خستۆتە ڕوو ^[١٤]^[١٥]

سەرچاوەکان[دەستکاری]

دەروازەی پزیشکی

^ "COVID-19 vaccine and treatments tracker (Choose vaccines or treatments tab, apply filters to view select data)". Milken Institute. 2020-11-03. Retrieved 2020-11-03. Lay summary.
^ "Biopharma products in development for COVID-19". BioWorld. 2020-11-02. Retrieved 2020-11-03.
^ "COVID-19 vaccine and therapeutics tracker". BioRender. 2020-10-30. Retrieved 2020-11-03.
^ Mullard A (April 2020). "Flooded by the torrent: the COVID-19 drug pipeline". Lancet. 395 (10232): 1245–1246. doi:10.1016/S0140-6736(20)30894-1. PMC 7162641. PMID 32305088.
^ Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. Retrieved 27 March 2020.
^ "First regulatory workshop on COVID-19 facilitates global collaboration on vaccine development". European Medicines Agency. 18 March 2020. Retrieved 21 March 2020.
^ "Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments" (Press release). U.S. Food and Drug Administration (FDA). 19 March 2020. Retrieved 21 March 2020.
^ "China approves first anti-viral drug against coronavirus Covid-19". Clinical Trials Arena. 18 February 2020. Retrieved 21 March 2020.
^ "Chinese Vaccine Approved for Human Testing at Virus Epicenter". Bloomberg News. 19 March 2020. Retrieved 21 March 2020.
^ Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (March 2020). "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics. 16 (6): 1232–1238. doi:10.1080/21645515.2020.1735227. PMC 7103671. PMID 32186952.
^ Zhang L, Liu Y (May 2020). "Potential interventions for novel coronavirus in China: A systematic review". Journal of Medical Virology. 92 (5): 479–490. doi:10.1002/jmv.25707. PMC 7166986. PMID 32052466.
^ Fox M (19 March 2020). "Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?". Stat. Retrieved 21 March 2020.
^ Chan M (19 March 2020). "Chinese military scientists ordered to win global race to develop coronavirus vaccine". South China Morning Post. Retrieved 22 March 2020.
^ COVID-19 Clinical Research Coalition (April 2020). "Global coalition to accelerate COVID-19 clinical research in resource-limited settings". Lancet. 395 (10233): 1322–1325. doi:10.1016/s0140-6736(20)30798-4. PMC 7270833. PMID 32247324.
^ Maguire BJ, Guérin PJ (2 April 2020). "A living systematic review protocol for COVID-19 clinical trial registrations". Wellcome Open Research. 5: 60. doi:10.12688/wellcomeopenres.15821.1. ISSN 2398-502X. PMC 7141164. PMID 32292826.

[1] "COVID-19 vaccine and treatments tracker (Choose vaccines or treatments tab, apply filters to view select data)". Milken Institute. 2020-11-03. Retrieved 2020-11-03. Lay summary.

[2] "Biopharma products in development for COVID-19". BioWorld. 2020-11-02. Retrieved 2020-11-03.

[3] "COVID-19 vaccine and therapeutics tracker". BioRender. 2020-10-30. Retrieved 2020-11-03.

[4] Mullard A (April 2020). "Flooded by the torrent: the COVID-19 drug pipeline". Lancet. 395 (10232): 1245–1246. doi:10.1016/S0140-6736(20)30894-1. PMC 7162641. PMID 32305088.

[5] Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. Retrieved 27 March 2020.

[6] "First regulatory workshop on COVID-19 facilitates global collaboration on vaccine development". European Medicines Agency. 18 March 2020. Retrieved 21 March 2020.

[7] "Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments" (Press release). U.S. Food and Drug Administration (FDA). 19 March 2020. Retrieved 21 March 2020.

[8] "China approves first anti-viral drug against coronavirus Covid-19". Clinical Trials Arena. 18 February 2020. Retrieved 21 March 2020.

[9] "Chinese Vaccine Approved for Human Testing at Virus Epicenter". Bloomberg News. 19 March 2020. Retrieved 21 March 2020.

[10] Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (March 2020). "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics. 16 (6): 1232–1238. doi:10.1080/21645515.2020.1735227. PMC 7103671. PMID 32186952.

[11] Zhang L, Liu Y (May 2020). "Potential interventions for novel coronavirus in China: A systematic review". Journal of Medical Virology. 92 (5): 479–490. doi:10.1002/jmv.25707. PMC 7166986. PMID 32052466.

[12] Fox M (19 March 2020). "Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?". Stat. Retrieved 21 March 2020.

[13] Chan M (19 March 2020). "Chinese military scientists ordered to win global race to develop coronavirus vaccine". South China Morning Post. Retrieved 22 March 2020.

[14] COVID-19 Clinical Research Coalition (April 2020). "Global coalition to accelerate COVID-19 clinical research in resource-limited settings". Lancet. 395 (10233): 1322–1325. doi:10.1016/s0140-6736(20)30798-4. PMC 7270833. PMID 32247324.

[15] Maguire BJ, Guérin PJ (2 April 2020). "A living systematic review protocol for COVID-19 clinical trial registrations". Wellcome Open Research. 5: 60. doi:10.12688/wellcomeopenres.15821.1. ISSN 2398-502X. PMC 7141164. PMID 32292826.

[١]

[٢]

[٣]

[٤]

[٥]

[٦]

[٧]

[٨]

[٩]

[١٠]

[١١]

[١٢]

[١٣]

[١٤]

[١٥]